Rep. Anna Eshoo (D-CA) (Graeme Sloan/AP Images)
June 23, 2022 12:17 PM EDTUpdated 12:58 PM
FDA+
Law

Fight over where to house ARPA-H still brews with House bil­l's pas­sage

Zachary Brennan

Senior Editor

The Biden ad­min­is­tra­tion isn’t back­ing down from its de­sire to keep a new drug ac­cel­er­a­tor, known as ARPA-H, in­side the Na­tion­al In­sti­tutes of Health. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times